Genetic Variant Ups Heart Failure Risk in Black Americans
May 14, 2024
-
2 min
A recent study highlights the impact of the V142I variant of the transthyretin gene on heart failure (HF) and mortality in Black Americans. Carriers of this variant face a significantly higher risk of HF hospitalization by age 63 and all-cause mortality by age 72, contributing to approximately 1 million years of life lost among Black Americans aged 50 years and older. The findings underscore the importance of early identification and treatment of V142I carriers with ATTRv-CA to mitigate the significant public health impact.
1. V142I variant of transthyretin gene increases HF risk in Black Americans2. Carriers face higher risk of HF hospitalization by age 63 and all-cause mortality by age 723. Estimated reduction in longevity ranges from 1.9 to 2.8 years4. Early identification and treatment of V142I carriers with ATTRv-CA is crucial5. Study published in JAMA reveals impact of the genetic variation on cardiovascular risks and public health
Listen Tab content